Dublin, Ireland - 28 May 2021: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) today announced that its shareholders approved all agenda items at today's virtual annual general meeting of shareholders.

7.227.632 ordinary shares in the capital of Cosmo were represented at this virtual annual general meeting of shareholders constituting 50.29% of the total outstanding ordinary shares in the capital of Cosmo (as of the record date). 
 

• The proposal to adopt the annual accounts of financial year 2020 ("FY 2020") was adopted by the general meeting of shareholders with 99.97% of the votes represented.
   
• The proposal to grant discharge to the members of the Board of Directors in respect of their performed management, supervision and advice during FY 2020 was adopted by the general meeting of shareholders with 99.80% of the votes represented.
   
• The proposal to grant options to subscribe for ordinary shares and/or rights to acquire ordinary shares to the Board of Directors was adopted by the general meeting of shareholders with 91.19% of the votes represented.
   
• The proposal to authorise the Board of Directors for a period of eighteen (18) months to issue - and grant subscription rights to - ordinary shares up to a maximum nominal sum of ten percent (10%) and, in the event of a merger, an acquisition or a strategic alliance to increase this authorisation by a maximum of a further ten percent (10%) of the ordinary shares included in the authorised capital was adopted by the general meeting of shareholders with 95.58% of the votes represented.
   
• The proposal to authorise the Board of Directors for a period of eighteen (18) months to issue ordinary shares up to a maximum nominal sum of twenty percent (20%) of the ordinary shares included in the authorised capital, which shares shall be issued for the execution of Cosmo's employee stock ownership plan for directors, employees, co-workers and administrators of Cosmo or a group company was adopted by the general meeting of shareholders with 91.19% of the votes represented.
   
• The proposal to authorise the Board of Directors for a period of eighteen (18) months to issue preferred shares or to grant the right to subscribe for preferred shares up to the maximum number as provided for in Cosmo's articles of association was adopted by the general meeting of shareholders with 92.82% of the votes represented.
   
• The proposal to authorise the Board of Directors to acquire fully paid-up shares in the share capital of Cosmo up to a maximum of ten percent (10%) of the ordinary shares included in the authorised capital and for a period of eighteen (18) months was adopted by the general meeting of shareholders with 99.47% of the votes represented.
   
• The proposal to irrevocably authorise the Board of Directors for a subsequent period of five (5) years to limit or exclude pre-emptive rights on any issue of ordinary shares was adopted by the general meeting of shareholders with 90.41% of the votes represented.
   
• The proposal to reappoint BDO Audit & Assurance B.V. (Amsterdam) as independent auditor of Cosmo for the financial year 2021 was adopted by the general meeting of shareholders with 100.00% of the votes represented.
   
• The proposal to appoint Mr. David Maris as non-executive member of the Board of Directors for a period of one (1) year as of the date of this AGM or the date of the AGM in 2022 (which ever date comes sooner) was adopted by the general meeting of shareholders with 94.71% of the votes represented.

About Cosmo Pharmaceuticals
Cosmo is a specialty pharmaceutical company focused on developing and commercialising products to treat selected gastrointestinal disorders and improve endoscopy quality measures through aiding the detection of colonic lesions. Cosmo has also developed medical devices for endoscopy and has a partnership with Medtronic for the global distribution of GI Genius(TM) its artificial intelligence device that uses artificial intelligence to help detect potential signs of colon cancer. Cosmo has licensed Aemcolo(R) to Red Hill Biopharma Ltd. for the US and has licensed Relafalk(R) to Dr. Falk Gmbh for the EU and other countries. For additional information on Cosmo and its products please visit the Company's website: www.cosmopharma.com

Contact
Niall Donnelly, CFO & Head of Investor Relations
Cosmo Pharmaceuticals N.V.                                  
Tel: +353 1 817 03 70
ndonnelly@cosmopharma.com